Phase 2 Brain Cancer Trial, Recruiting (NCT04197297)

Phase 2 Brain Cancer Trial, Recruiting NCT04197297 Sponsor: University Health Network, Toronto Condition: Brain Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT04197297 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Brain Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a primary cancer (confirmed by a biopsy), and brain scans show that the cancer has spread to the brain
At least one of the tumors in the brain is larger than 1 cm across and shows no signs of bleeding on scans
You are 18 years of age or older
You are already scheduled to receive radiation therapy to the brain metastases (cancer that has spread to the brain)
You are able to understand the study and are willing to sign a consent form agreeing to take part

Who may not be able to join:

You have previously received whole brain radiation therapy
You have previously had radiosurgery (a focused, high-dose radiation treatment) directed at the specific tumor being studied in this trial
You are unable to have an MRI scan with contrast dye for any reason (for example, a pacemaker, kidney problems, or allergy to the dye)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Catherine Coolens, Ph. D, Princess Margaret Cancer Center - UHN

Phone: 416-946-6899

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04197297

Sponsor: University Health Network, Toronto

Phase: Phase 2

Status: Recruiting

Condition: Brain Cancer

Trial contact: 416-946-6899

More information: https://clinicaltrials.gov/study/NCT04197297

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a primary cancer (confirmed by a biopsy), and brain scans show that the cancer has spread to the brain
At least one of the tumors in the brain is larger than 1 cm across and shows no signs of bleeding on scans
You are 18 years of age or older
You are already scheduled to receive radiation therapy to the brain metastases (cancer that has spread to the brain)
You are able to understand the study and are willing to sign a consent form agreeing to take part

Who may not be able to join:

You have previously received whole brain radiation therapy
You have previously had radiosurgery (a focused, high-dose radiation treatment) directed at the specific tumor being studied in this trial
You are unable to have an MRI scan with contrast dye for any reason (for example, a pacemaker, kidney problems, or allergy to the dye)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

University Health Network, Toronto

Registry

ClinicalTrials.gov

Start date

5 October 2021

Est. completion

1 June 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Response Assessment in Neuro-Oncology (RANO) to validate biomarkers; Response Evaluation Criteria in Solid Tumors (RECIST) criteria to validate biomarkers; Progression Free Survival (PFS) to validate biomarkers

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov